Tumor-Nipple Distance of ≥ 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy

[1]  M. Morrow,et al.  Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes , 2019, Annals of Surgical Oncology.

[2]  Ah Young Park,et al.  MRI diagnostic features for predicting nipple-areolar-complex involvement in breast cancer. , 2019, European journal of radiology.

[3]  Hee Jun Choi,et al.  Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm , 2019, Journal of breast cancer.

[4]  Y. Sagara,et al.  National Patterns of Breast Reconstruction and Nipple-Sparing Mastectomy for Breast Cancer, 2005–2015 , 2019, Annals of Surgical Oncology.

[5]  A. Degnim,et al.  Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications , 2019, Annals of Surgical Oncology.

[6]  A. Bartholomew,et al.  Neoadjuvant Chemotherapy and Nipple-Sparing Mastectomy: Timing and Postoperative Complications , 2019, Annals of Surgical Oncology.

[7]  A. Vingiani,et al.  Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients , 2018, Annals of Surgical Oncology.

[8]  N. Houssami,et al.  Preoperative MRI evaluation of lesion-nipple distance in breast cancer patients: thresholds for predicting occult nipple-areola complex involvement. , 2018, Clinical Radiology.

[9]  E. Connolly,et al.  Expanding the Criteria for Nipple‐Sparing Mastectomy in Patients With Poor Prognostic Features , 2018, Clinical breast cancer.

[10]  C. Hudis,et al.  Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. , 2017, The oncologist.

[11]  R. Simmons,et al.  Oncologic Outcomes After Nipple-Sparing Mastectomy , 2016, Annals of Surgical Oncology.

[12]  Paolo Morandi,et al.  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. , 2016, The Lancet. Oncology.

[13]  J. Lee,et al.  Feasibility of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumor-Nipple Distance Less Than 2.0 cm , 2016, World Journal of Surgery.

[14]  U. de Paula,et al.  Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy. , 2015, Breast.

[15]  R. Ponzone,et al.  MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. , 2015, European journal of cancer.

[16]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[17]  Phoebe E. Freer,et al.  Increasing Eligibility for Nipple-Sparing Mastectomy , 2013, Annals of Surgical Oncology.

[18]  P. Sismondi,et al.  Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. , 2012, European journal of cancer.

[19]  Barbara L. Smith,et al.  Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Freeman,et al.  Applicability of the Nipple-Areola Complex-Sparing Mastectomy: A Prediction Model Using Mammography to Estimate Risk of Nipple-Areola Complex Involvement in Breast Cancer Patients , 2006, Annals of plastic surgery.

[21]  G. Robb,et al.  The Incidence of Occult Nipple-Areola Complex Involvement in Breast Cancer Patients Receiving a Skin-Sparing Mastectomy , 1999, Annals of Surgical Oncology.